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Abstract
Carnitine	is	essential	for	energy	metabolism	and	spermatozoa	maturation.	Combining	
L‐carnitine	 and	 L‐acetylcarnitine	 with	 micronutrients	 has	 been	 investigated	 as	 a	
treatment for infertility in men. We evaluated the effects of a therapeutic formula‐
tion,	Proxeed	Plus,	on	sperm	parameters	in	oligoasthenozoospermic	men.	This	pro‐
spective,	 randomised,	 double‐blind,	 placebo‐controlled	 clinical	 trial	 involved	 175	
males	 (19–44	years)	with	 idiopathic	oligoasthenozoospermia	who	failed	to	 impreg‐
nate	their	partners	 (12	months).	Males	received	Proxeed	Plus	or	placebo	for	3	and	
6	months.	 Sperm	 volume,	 progressive	motility	 and	 vitality	 significantly	 (p < 0.001) 
improved	after	6	months	compared	to	baseline.	Sperm	DNA	fragmentation	index	sig‐
nificantly decreased compared to baseline (p < 0.001) and the 3‐month therapy 
(p = 0.014) in treated men. Increased seminal carnitine and α‐glucosidase concentra‐
tion	also	positively	correlated	with	 improved	progressive	motility.	Decreased	DNA	
fragmentation	index	was	the	good	predictor	of	progressive	sperm	motility	>10%,	and	
simultaneous	 measurement	 of	 changes	 in	 sperm	 vitality	 and	 DNA	 fragmentation	
index	 gave	 the	 highest	 probability	 of	 sperm	 motility	 10%	 (AUC	=	0.924;	 95%	
CI = 0.852–0.996; p	<	0.001).	Logistic	regression	analyses	revealed	DNA	fragmenta‐
tion	 index	 decrease	 as	 the	 only	 independent	 predictor	 of	 sperm	 motility	 10%	
(OR = 1.106; p = 0.034). We have demonstrated the beneficial effects of carnitine 
derivatives	on	progressive	motility,	vitality	and	sperm	DNA	fragmentation.	Combining	
metabolic and micronutritive factors is beneficial for male infertility.
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1  | INTRODUC TION
Male fertility issues are major contributors to infertility in cou‐
ples,	accounting	for	approximately	50%	of	these	cases	 (Agarwal,	
Mulgund,	Hamada,	&	Chyatte,	2015).	The	causes	of	male	infertility	
remain	unknown,	and	are	ambiguous	in	almost	40%–60%	of	these	
patients	(Gabrielsen	&	Tanrikut,	2016).	Due	to	the	unclear	causes	
of	idiopathic	male	infertility,	the	main	challenge	involves	the	selec‐
tion	of	a	therapeutic	modality.	Since	patients	with	oligoastheno‐
zoospermia	represent	a	very	diverse	group,	treating	this	particular	
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group	 is	not	 an	easy	 task.	As	 a	possible	 treatment	option,	 some	
food	supplements	may	 improve	seminal	 fluid	conditions,	provide	
energy	to	male	germ	cells	and	protect	these	cells	 from	oxidative	
stress.	 Since	 spermatogenesis	 is	 an	 energy‐intensive	 process,	 it	
requires	 a	 highly	 balanced	 supply	 of	 minerals,	 antioxidants	 and	
nutrients.
Oxidative	stress,	sperm	apoptosis	and	DNA	damage	significantly	
contribute	 to	 the	pathogenesis	 of	male	 infertility	 (Agarwal	&	Said	
2004).	Sperm	DNA	damage	is	associated	with	reduced	fertility	and	
increased	frequency	of	spontaneous	abortions,	and	affects	embryo	
quality	(Lewis	et	al.,	2013).	Moreover,	it	is	considered	a	potential	pre‐
dictor	of	 fertility,	and	 its	detection	has	 repeatedly	been	described	
as a prognostic parameter of male fertility in various assisted repro‐
duction	techniques	and	andrological	diagnostics	(Agarwal,	Majzoub,	
&	 Esteves,	 2016;	 Bungum	 et	 al.,	 2007;	 Cho,	 Agarwal,	Majzoub,	&	
Esteves,	2017;	Henkel	et	al.,	2004).
L‐carnitine	 (LC)	plays	a	major	 role	 in	 the	oxidation	of	 long‐chain	
fatty	 acid,	 and	 its	 active	 form,	 L‐acetylcarnitine	 (ALC),	 protects	mi‐
tochondria	 from	 metabolic	 toxins	 via	 its	 antioxidant	 effects.	 ALC	
also	 stabilises	 cell	 membranes	 and	 exerts	 anti‐apoptotic	 actions	
(Abdelrazik,	 Sharma,	Mahfouz,	&	Agarwal,	2009;	Kerner	&	Hoppel,	
1998;	Vanella	et	al.,	2000;	Zhou,	Liu,	&	Zhai,	2007).	LC	absorbed	by	
epididymal cells is released into the epididymal lumen and luminal part 
of	the	seminiferous	epithelium.	The	concentration	of	LC	 in	 the	epi‐
didymal	lumen	and	in	sperm	cells	is	approximately	2,000‐fold	greater	
than	in	the	circulating	serum,	implying	it	plays	a	very	important	role	
in	sperm	maturation,	metabolism	and	motility	(Mongioi	et	al.,	2016).
Since	the	epididymis	plays	an	essential	role	in	sperm	maturation,	
progressive motility and the achievement of fertilisation capacity by 
male	germ	cells,	several	markers	can	be	used	to	evaluate	epididymal	
function,	including	LC	(Cooper,	1990;	Haidl	&	Schill,	1997)	or	α‐glu‐
cosidase	 (Cooper,	 Yeung,	Nathan,	&	Nieschlag,	 1988;	Garcia	Diez,	
Esteban	Ruiz,	&	Vilar,	1992).
Positive	 correlations	 between	 seminal	 carnitine	 concentration,	
sperm count and motility have been demonstrated in clinical studies 
(Matalliotakis	et	al.,	2000;	Menchini‐Fabris,	Canale,	Izzo,	Olivieri,	&	
Cartelloni,	1984;	Mongioi	et	al.,	2016).	Several	 randomised	studies	
assessing the effects of different daily doses of carnitine on sperm 
parameters	 in	 idiopathic	 oligoasthenozoospermic	 men	 have	 been	
published.	In	two	studies,	which	included	100	and	60	infertile	men,	
respectively	(Lenzi	et	al.,	)	sperm	concentration,	motility	and	linearity	
were	shown	to	increase.	Similar	results	were	obtained	by	Balercia	et	
al.	 (2005)	who	examined	60	men	with	 oligoasthenozoospermia.	 In	
52	men	 treated	with	 clomifene,	 carnitine	 resulted	 in	higher	 sperm	
concentration	 and	 motility	 (Moradi,	 Moradi,	 Alemi,	 &	 Ahmadnia,	
2010).	In	an	open	study	comprising	of	114	oligoasthenozoospermic	
men,	Busseto	et	al.	(2012)	observed	increased	sperm	motility,	while	
Sigman,	 Glass,	 Campagnone,	 &	 Pryor	 (2006)	 found	 no	 effects	 on	
sperm	motility	or	total	motile	count	in	a	group	of	21	asthenozoosper‐
mic men.
In	 light	 of	 these	 positive	 indications,	we	 aimed	 to	 evaluate	 the	
effect	 of	 a	 combined	 formulation,	 Proxeed	 Plus,	 on	 sperm	 and	
seminal	 biochemical	 parameters,	 in	 a	 randomised,	 double‐blind,	
placebo‐controlled	clinical	trial	with	idiopathic	oligoasthenozoosper‐
mic men who failed to impregnate their wives over the past 12 months.
2  | PATIENTS AND METHODS
2.1 | Patients and study design
This	 prospective,	 randomised,	 double‐blind,	 placebo‐controlled	
clinical trial was approved by the institutional review board of the 
Association	 of	 Serbian	 Private	 Healthcare	 Providers,	 Belgrade,	
Serbia	(Institute	Ethical	Approval	Number	PXP‐001B/24).	After	ob‐
taining	written	 informed	consent	 from	participants,	 the	study	was	
conducted with 175 infertile men with idiopathic oligoastheno‐
zoospermia	in	the	Department	of	Andrology‐Uromedica	Polyclinic,	
Association	 of	 Serbian	 Private	 Healthcare	 Providers,	 Belgrade,	
Serbia.	Patients	 (mean	age,	31.5	years;	19–44	years)	were	enrolled	
between December 2014 and January 2016.
In	this	study,	the	effect	of	the	test	formulation,	Proxeed	Plus,	was	
investigated	 in	 idiopathic	 oligoasthenozoospermic	 men	 who	 were	
having trouble impregnating their partners for at least 12 months.
The	applied	test	formulation	consisted	of	1,000	g	LC,	0.5	g	ALC,	
0.725	g	fumarate,	 l	g	fructose,	50	mg	citric	acid,	10	mg	zinc,	20	mg	
coenzyme	Q10,	50	µg	selenium,	90	mg	vitamin	C,	200	µg	folic	acid	
and	1.5	µg	vitamin	B12.	The	placebo	was	made	with	the	excipients	
(sucrose,	 silica	 [anti‐caking],	 lemon	 flavour,	 acesulfame	 K	 [E950,	
sweetener])	of	the	supplementation	without	the	active	substances.
After	 2	months	 of	 “wash‐out”	 (period	 without	 any	 therapy),	
treatment	occurred	 for	6	months	with	Proxeed	Plus	 (125	patients)	
or	placebo	(50	patients),	followed	by	control	semen	analyses	3	and	
6	months	after	 therapy	 initiation	 (T3,	T6).	Patients	 received	either	
test	formulation,	Proxeed	Plus,	or	placebo	(two	times	per	day)	 in	a	
randomised,	double‐blind	fashion.
All	 participants	met	 the	 inclusion	 criteria	 of	 one	 semen	 analy‐
sis	that	demonstrated	either	total	sperm	number	≤15	million	per	ml;	
progressive	motility	<32%;	normal	viscosity	and	normal	leucocytes	
number (<1 × 106/ml); total ejaculate volume 1.0 ml; sperm vital‐
ity	≤58%	live;	normal	sperm	morphology	<4%	(according	to	WHO,	
2010).
The following female partners were included in the study:
•	 fertile	partners	with	regular	menstrual	cycles,	and	younger	than	
40 years;
• infertile partners provided no fertility‐ related procedures such as 
artificial	insemination	(AI),	in	vitro	fertilisation	(IVF)	or	intracyto‐
plasmic	sperm	injection	(ICSI)	were	planned	for	the	next	90	days.
Exclusion	 criteria	 for	 the	 male	 participants	 were	 as	 follows:	
motility	 <5%;	 sperm	 concentration	 <1	×	106/ml; history of unde‐
scended testes; subjects with known hypersensitivity to ingredients 
in	Proxeed	Plus;	endocrine	disorders	affecting	the	hypothalamic–pi‐
tuitary	axis;	history	of	post‐pubertal	mumps;	presence	of	anti‐sperm	
antibodies;	history	of	endocrine	disease;	autoimmune	disease,	cys‐
tic	fibrosis,	or	testicular	cancer;	leucocytospermia,	leucocyte	count	
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>1	×	106/ml;	use	of	antioxidant	agents	or	vitamins	within	the	8	weeks	
prior to inclusion in the study (for subjects using vitamin supplemen‐
tation,	an	8‐week	wash‐out	period	was	 required	prior	 to	 inclusion	
in the study); use of vitamin or natural treatment for infertility at 
any time; history of taking any therapy for infertility within the last 
2 months including over‐the‐counter treatment and vitamin sup‐
plementation;	history	of	excessive	consumption	of	alcohol	90	days	
prior to the start of the trial; subjects involved in other clinical trials.
2.2 | Preparation and analyses of semen samples
Semen	 samples	 were	 obtained	 after	 3	days	 of	 sexual	 abstinence	
at	 the	 Andrology	 Department	 of	 Uromedica	 Polyclinic,	 Belgrade,	
Serbia.	Samples	were	 liquefied	at	37°C	and	then	analysed	accord‐
ing	to	the	World	Health	Organization	(WHO)	criteria	(WHO,	2010).	
Remnants of liquefied semen samples were immediately centrifuged 
at	1,000	g for 10 min. The seminal plasma was divided into several 
aliquots	and	frozen	at	−80°C	for	biochemical	analysis.
Samples	were	scored	to	evaluate	motility;	 the	results	were	ex‐
pressed	 as	 motility	 and	 progressive	 motility.	 Sperm	 DNA	 defrag‐
mentation	 index	 (DFI)	 was	 determined	 by	 the	 sperm	 chromatin	
dispersion	test,	Halosperm	(Halotech	DNA,	S.L.	Madrid,	Spain).	To	
determine α‐glucosidase	activity,	a	20	µl	aliquot	of	seminal	plasma	
was incubated for 2 hr with p‐nitrophenyl‐α‐D‐glucopyranoside at 
37°C	(pH	6.8);	this	is	because	α‐glucosidase specifically hydrolyses 
p‐nitrophenyl‐α‐D‐glucopyranoside into p‐nitrophenol. The reac‐
tion	was	stopped	by	adding	1	ml	0.02	M	NaOH.	The	quantity	of	p‐
nitrophenol	was	measured	using	a	biochemistry	analyzer	(ContecBc	
300,	Beijing,	China)	at	a	wavelength	of	405	nm.
Seminal	LC	concentration	was	determined	enzymatically	using	a	
UV	test	(Roche	Diagnostics	GmbH,	Penzberg,	Germany).
2.3 | Statistical analysis
Normal	 distribution	 of	 the	 data	 was	 tested	 using	 Shapiro–Wilk	
test.	Since	distribution	of	 the	data	was	not	normal,	nonparametric	
tests were employed. Continuous variables are presented as me‐
dian values and interquartile ranges while categoric data are pre‐
sented as absolute or relative frequencies. Variables were compared 
using	Friedman	test	and	post	hoc	Wilcoxon	Signed	Rank	test,	with	
Bonferroni	corrections,	or	 in	case	of	monitoring	of	changes	 in	two	
points,	only	using	Wilcoxon	Signed	Rank	test.	Differences	between	
categoric	 variables	 were	 analysed	 using	 McNemar–Bowker	 test	
if the change was monitored in three points (for k × k contingency 
table)	or	McNemar	test	if	the	change	was	monitored	in	two	points	
(for 2 × 2 contingency tables).
We	calculated	per	cent	of	examined	parameters	change	between	
T0	and	T6.	For	parameters	which	levels	decreased	during	the	ther‐
apy	(e.g.,	DFI	values),	we	applied	formula	([T0	−	T6]/T0	×	100),	and	
for	 parameters	 which	 level	 increases	 in	 second	 point	 (e.g.,	 sperm	
vitality,	seminal	carnitine	concentration,	α‐glucosidase	activity),	per‐
centage	changes	are	calculated	by	([T6	−	T0]/T6	×	100)	formula.	Per	
cent	of	changes	calculated	for	examined	parameter	was	subject	for	
statistical analyses. Correlation between determined parameters 
was	 established	 using	 Spearman's	 rank	 correlation.	 Binary	 logistic	
regression analysis was used for testing of probability for increased 
motility	of	spermatozoa	by	10%,	20%	or	30%.	We	used	receiver	op‐
erating characteristic curve (ROC) analysis to evaluate biomarker use 
in	specific	clinical	decisions.	According	to	Swets	(1988),	criteria	for	
areas	 under	ROC	 curves	 (AUC),	 diagnostic	 tests	were	 categorised	
in the group with poor accuracy 0.5–0.7; satisfactory accuracy for 
certain	purposes	0.7–0.8;	good	accuracy	0.8–0.9	and	excellent	accu‐
racy	>0.9.	Variables	with	best	predictive	properties	were	combined	
TA B L E  1  Sperm	parameters	before	therapy	and	after	3	and	6	months	of	(A)	Proxeed	Plus	therapy.	(B)	Placebo	treatment
(A) Sperm parameters T0 T3 T6 p
Volume,	ml 3.00 (2.13–4.70) 3.20 (2.50–4.40)*  3.60 (2.60–4.50)*  0.020
DFI,	% 38.50 (32.00–48.70) 35.50 (25.50–44.00)*  31.00	(25,00–41,00)*,**  <0.001
Progressive	sperm	motility,	% 28.0 (12.0–38.0) 30.0 (12.0–39.0) 31.0 (20.0–41.0)**  <0.001
Vitality,	% 0.52 (0.43–0.60) 0.57 (0.46–0.64) 0.56 (0.47–0.65)*  0.002
Seminal	glucosidase	U/L 25.40 (20.00–42.88) N.D. 32.50 (23.00–42.83) 0.002
Carnitine,	µmol/L 724.6 (626.45–800.48) N.D. 782.8 (686.55–926.25) <0.001
(B) Sperm parameters T0 T3 T6 p
Volume,	mL 3.3 (2.9–3.9) 3.1 (2.85–3.70) 3.40 (3.00–3.90) 0.127
DFI,	% 37.00 (34.50–41.00) 38.00 (35.50–40.50) 38.00 (34.00–39.00) 0.306
Progressive	sperm	motility,	% 23.0 (18.0–28.0) 24.0 (19.5–29.0) 24.00 (20.0–28.0) 0.098
Seminal	glucosidase	U/L 23.50 (20.90–27.95) N.D. 23.50 (21.6–27.95) 0.084
Carnitine,	µmol/L 710.0 (682.45–733.40) N.D. 709.5 (699.7–722.6) 0.580
Notes.	N.D.:	not	determined.
Data	are	presented	as	median	values	(25th–75th	percentiles).	Comparison	was	performed	by	Friedman	test	(for	three	dependent	populations).
*Significant	difference	compared	to	the	values	obtained	before	therapy.
**Significant	difference	compared	to	the	values	obtained	3	months	after	therapy;	Post	hoc	test	is	the	Wilcoxon	Signed	Ranks	test	with	Bonferroni	
correction.
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in order to produce a model with the best discriminatory properties 
and areas under curves were presented as C‐statistic.
A	p‐value	≤0.05	was	considered	statistically	significant.	Statistical	
data	 processing	 was	 performed	 using	 Statistical	 Package	 for	 the	
Social	Sciences	PASW®	Statistic	v.	22	(Chicago,	IL,	USA)	software.
3  | RESULTS
Sperm	parameters	were	tested	before	(T0),	as	well	as	three	(T3)	and	
six	(T6)	months	after	the	start	of	Proxeed	Plus	or	placebo	therapy.	
The	results	obtained	are	presented	in	Table	1A,B.
Statistically	significant	differences	were	observed	for	ejaculate	
volume,	progressive	motility,	vitality	and	DFI	between	the	three	dif‐
ferent time points. There were also significant differences in seminal 
carnitine concentration and seminal α‐glucosidase activity before 
therapy	(T0),	and	after	6	months	of	therapy	(T6).
Values of most sperm parameters such as ejaculate volume 
(p	=	0.001),	progressive	sperm	motility	(p < 0.001) and sperm vitality 
(p	=	0.002)	were	significantly	higher	at	T6	compared	to	T0.	A	signif‐
icant increase in progressive motility (p = 0.004) was only observed 
after	6	months	of	therapy	(T6).	DFI	significantly	decreased	from	T0	to	
T3 (p < 0.001) with an additional decrease after 6 months of treatment 
(T6: p	=	0.01).	In	contrast,	subjects	who	received	the	placebo	showed	
no changes after 3 and 6 months of treatment (Table 1B).
We	calculated	median	changes	for	DFI,	seminal	carnitine,	vitality	
and α‐glycosidase activity between T0 and T6. Median decrease in 
DFI	levels	was	21%,	and	median	increase	in	seminal	carnitine,	vitality	
and α‐glucosidase	activity	was	6.5%,	6%	and	8.3%	respectively.
We	examined	the	per	cent	of	patients	with	three	levels	of	pro‐
gressive	sperm	motility	at	the	three	points	(T0,	T3,	T6),	and	present	
sperm motility as a percentage (Table 2). The proportion of men with 
progressive	sperm	motility	10,	between	10%	and	20%,	and	20%	at	
the	three	points	(T0,	T3,	T6)	displayed	significant	changes	(p = 0.001).
In	addition,	we	examined	the	change	in	the	percentage	of	sub‐
jects	with	progressive	sperm	motility	<10%	and	>10%	between	the	
time	points,	T0	and	T6	 (2	×	2	contingency	 tables).	The	percentage	
of	subjects	with	sperm	motility	>10%	was	not	significantly	higher	at	
T6	(83.4%)	when	compared	to	T0	(79.4%;	p	=	0.267).	A	similar	anal‐
ysis was performed to test the changes in percentage of men with 
progressive	sperm	motility	above	and	below	20%	and	percentage	of	
men	with	sperm	motility	above	and	below	30%.	A	statistically	sig‐
nificant increase in the percentage of males with progressive sperm 
motility	 above	 20%	was	 observed	 at	 T6	 (73.4%)	 compared	 to	 T0	
(61.55%;	p	=	0.007).	After	investigating	the	proportion	of	men	with	
progressive	sperm	motility	higher	than	30%,	an	increase	was	not	ob‐
served	at	T6	(51.1%)	compared	to	T0	(44.4%;	p = 0.286).
We analysed the correlation between progressive sperm motil‐
ity and percentage change between T0 and T6. The higher reduction 
of	DFI	between	the	time	points	 (T0	versus	T6)	was	associated	with	
greater sperm motility (R	=	0.269,	p = 0.024). This finding is similar to 
seminal	carnitine	concentration	and	sperm	vitality.	A	higher	increase	
in seminal carnitine and vitality resulted in a greater progressive 
sperm motility (R	=	0.274,	p = 0.023 for carnitine; R	=	0.033,	p = 0.008 
for sperm vitality). Changes in other parameters between the two pe‐
riods (T0 versus T6) had no significant influence on sperm motility.
TA B L E  2   Percentage of patients with different levels of 
progressive	sperm	motility	before	and	during	Proxeed	Plus	therapy
Sperm motility T0 T3 T6 p
<10% 20.9 16.7 16.6 0.001
10%–20% 17.6 16.7 10.0  
>20% 61.5 66.7 73.4  
Note. Progressive sperm motility is presented as a percentage. 
Comparison	was	performed	by	McNemar–Bowker	test.
Sperm parameters OR (95% CI) AUC (95% IP)
Carnitine	increase	between	T0/T6	(%) 1.041 (1.001–1.082) 
p = 0.046
0.713 
(0.591–0.815) 
p = 0.009
α‐Glucosidase activity increase between 
T0/T6	(%)
1α0.021 (1.001–1.042) 
p = 0.048
0.688 
(0.571–0.789) 
p = 0.020
Volume	increase	between	T0/T6	(%) 1.000 (0.991–1.008) 
p = 0.911
0.604 
(0.481–0.718) 
p = 0.256
Sperm	vitality	increase	between	T0/T6	(%) 1.064 (1.016–1.115) 
p = 0.009
0.836 
(0.728–0.913) 
p < 0.001
DFI	decrease	between	T0/T6	(%) 1.105 (1.035–1.178) 
p = 0.003
0.793 
(0.686–
0.877) 
p < 0.001
Notes.	AUC:	area	under	ROC	curve;	CI:	confidence	interval;	OR:	odds	ratio.
Percentage change between T0 and T6.
TA B L E  3   Influence of per cent changes 
in the studied parameters on a greater 
than	10%	progressive	increase	in	sperm	
motility after 6 months of therapy
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Using	logistic	regression	analysis,	we	calculated	the	probability	of	
a change in the tested parameters between T0 and T6 to predict the 
likelihood	of	males	having	a	sperm	motility	10%	at	T6	(Table	3;	i.e.,	
predictive capability of change in the studied parameters between 
the two periods was evaluated to identify men with sperm motility 
10%	at	T6).	A	1%	increase	in	sperm	vitality	increased	the	probability	
of	a	10%	sperm	motility	by	1.064‐fold	after	6	months	of	therapy.	In	
contrast,	a	1%	decrease	 in	DFI	resulted	 in	a	1.105‐fold	 increase	 in	
the	probability	of	a	higher	than	10%	sperm	motility.	Positive	changes	
in α‐glucosidase and carnitine concentration were associated with 
the	 increased	 likelihood	 of	 a	 10%	 sperm	 motility;	 however,	 their	
influence is marginally significant (p = 0.048 for α‐glucosidase and 
p = 0.046 for carnitine).
Receiver operating characteristic curve analysis was used to test 
the diagnostic capacity of a percentage change in the studied parame‐
ters	to	identify	individuals	with	10%	sperm	motility.	Changes	in	sperm	
vitality	 showed	 the	 best	 diagnostic	 characteristics	 as	 AUC	was	 0.8	
(based	on	Sweats	criteria,	this	value	defines	good	diagnostic	capacity).	
Percentage	decrease	in	DFI	is	less	accurate	compared	to	spermatozoa	
vitality,	 but	 its	 diagnostic	 capacity	 may	 also	 be	 defined	 as	 good.	
Carnitine increase showed a satisfactory capacity to detect individuals 
with	10%	sperm	motility	(its	AUC	is	moderately	0.7).	The	AUC	for	in‐
crease in α‐glucosidase	activity	was	not	satisfactory,	and	the	increase	
in the diagnostic capacity of volume was not statistically significant.
The parameter changes between T0 and T6 that are related to 
20%	(Table	4)	and	30%	(Table	5)	progressive	motility	were	analysed	
in a similar manner. Increased sperm vitality showed the best predic‐
tive	values.	Males	with	a	parameter	increase	of	1%	had	a	1.119‐fold	
higher	probability	of	a	spermatozoa	progressive	motility	20%	after	
6 months of therapy when compared to individuals lacking a record 
of	 increase	 in	 this	parameter.	Additionally,	 the	diagnostic	 capacity	
of	this	parameter	is	included	in	the	list	of	tests	possessing	excellent	
characteristics	 (AUC	0.9).	 Per	 cent	DFI	 decrease	 is	 the	only	 other	
parameter	that	may	predict	a	sperm	motility	20%	(OR	=	1.064);	how‐
ever,	its	capacity	to	diagnose	individuals	with	a	sperm	motility	20%	is	
not	relevant	from	a	clinical	viewpoint	(AUC	0.7).
Significant	predictors	of	a	30%	progressive	motility	were	the	in‐
crease in seminal carnitine concentration and α‐glucosidase	activity,	
Sperm parameter T0/T6 (%) OR (95% CI) AUC (95% CI)
Carnitine increase between T0/T6 
(%)
1.030 (1.000–1.062) 
p = 0.052
0.636 (0.500–0.772) 
p = 0.083
α‐Glucosidase activity increase 
between	T0/T6	(%)
1.064 (1.014–1.117) 
p = 0.011
0.689 (0.542–0.836) 
p = 0.014
Volume	increase	between	T0/T6	(%) 0.995 (0.989–1.002) 
p = 0.154
0.500 (0.344–0.656) 
p = 0.995
Sperm	vitality	increase	between	T0/
T6	(%)
1.119 (1.052–1.190) 
p < 0.001
0.908 (0.831–0.984) 
p < 0.001
DFI	decrease	between	T0/T6	(%) 1.015 (1.000–1.030) 
p = 0.054
0.671 (0.526–0.817) 
p = 0.029
Notes.	AUC:	area	under	ROC	curve;	CI:	confidence	interval;	OR:	odds	ratio.
Percentage change between T0 and T6
TA B L E  4   Influence of percentage 
change in studied parameters after 
6‐month therapy on progressive increase 
in	sperm	motility	greater	than	20%
Sperm parameter OR (95% CI) AUC (95% CI)
Carnitine	increase	between	T0/T6	(%) 1.024 (1.001–1.049) 
p = 0.049
0.617 
(0.482–0.752) 
p = 0.096
α‐Glucosidase activity increase between 
T0/T6	(%)
1.051 (1.006–1.097) 
p = 0.026
0.541 
(0.408–0.673) 
p = 0.557
Volume	increase	between	T0/T6	(%) 0.998 (0.992–1.005) 
p = 0.633
0.650 
(0.538–0.762) 
p = 0.080
Sperm	vitality	increase	between	T0/T6	(%) 1.008 (0.992–1.025) 
p = 0.329
0.525 
(0.391–0.660) 
p = 0.722
DFI	decrease	between	T0/T6	(%) 1.012 (1.001–1.024) 
p = 0.042
0.556 
(0.422–0.690) 
p = 0.556
Notes.	AUC:	area	under	ROC	curve;	CI:	confidence	interval;	OR:	odds	ratio.
Percentage change between T0 and T6.
TA B L E  5   Influence of per cent changes 
in the tested parameters on a greater than 
30%	progressive	increase	in	sperm	
motility after 6 months of therapy
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and	 the	decrease	 in	DFI	 (Table	6).	None	of	 the	parameters	 tested	
showed satisfactory diagnostic characteristics in the detection of 
sperm	motility	30%.
For	each	parameter	change	demonstrating	good	diagnostic	accu‐
racy	(AUC	0.7),	we	determined	their	optimal	cut‐off	values	to	discrim‐
inate	subjects	with	sperm	motility	10%	from	those	with	10%	sperm	
motility.	 A	 similar	 analysis	was	 performed	 to	 discriminate	 patients	
with	sperm	motility	20%	from	those	with	10%	motility	(Table	6).
For	sperm	vitality	per	cent	increase	after	6	months,	the	optimal	
cut‐off	value	for	men	with	10%	sperm	motility	compared	to	those	
with	 a	 value	10%	was	5.9%	 (PPV	=	100%).	 The	 same	 results	were	
obtained	 when	men	 with	 sperm	motility	 20%	were	 discriminated	
from	those	with	20%	motility.	For	DFI	changes,	the	optimal	cut‐off	
value	when	 subjects	with	 sperm	motility	 10%	were	 discriminated	
from	those	with	10%	sperm	motility	was	3%	(PPV	=	96%).	If	DFI	de‐
creased	by	3%	after	6	months	of	therapy,	there	was	a	96%	chance	
that	the	patient	would	have	a	sperm	motility	10%.	For	carnitine	in‐
crease	after	6	months,	the	optimal	cut‐off	value	to	detect	men	with	
a	sperm	motility	10%	was	7.7%.	Among	those	men	who	had	an	in‐
creased	carnitine	per	cent	7.7%	after	6	months	of	therapy,	probabil‐
ity	of	sperm	motility	10%	was	97.2%	(PPV	=	97.2%).
In	addition,	we	combined	the	parameters	 to	better	 identify	 in‐
dividuals	with	 sperm	motility	 10%	 or	 20%.	 Simultaneous	 changes	
in	 sperm	vitality	 and	DFI	 after	 6	months	of	 therapy	were	demon‐
strated to reveal the highest diagnostic accuracy when used to 
detect	 individuals	with	a	sperm	motility	10%;	diagnostic	accuracy:	
AUC	=	0.924,	 95%	 CI	 (0.852–0.996),	 p	<	0.001.	 Application	 of	 the	
same	analysis	to	identify	individuals	with	a	sperm	motility	20%	did	
not reveal an increase in accuracy after combination compared to 
determining individual changes in sperm vitality.
4  | DISCUSSION
Increasing	male	 fertility	problems,	which	are	demonstrated	by	de‐
creases	 in	 sperm	 concentration	 and	 the	 motility	 of	 spermatozoa,	
have	been	reported	 in	Western	countries	 (Levine	et	al.,	2017)	and	
India	(Adiga,	Jayaraman,	Kalthur,	Upadhya,	&	Kumar,	2008).
Recent	 studies	 have	 indicated	 the	 important	 role	 of	 nutrients,	
vitamins	and	minerals	in	sperm	health	(Balercia	et	al.,	2005;	Lenzi	et	
al.,	2003).	LC	and	ALC	are	present	in	high	concentration	in	the	epi‐
didymis,	and	play	crucial	roles	in	the	development,	maturation	and	
metabolism	of	 spermatozoa	 (Radigue,	 Es‐slami,	&	 Soufir,	 1996)	 by	
improving	sperm	motility,	and	displaying	antioxidant	and	anti‐apop‐
totic	properties	for	 the	stabilisation	of	 the	spermatozoa	cell	mem‐
brane	(Cheah	&	Yang,	2011).
In	this	study,	we	aimed	to	investigate	the	effects	of	combination	
therapy	using	metabolic	substances	(LC	and	ALC),	antioxidants	and	
vitamins	 in	 a	 randomised,	double‐blind,	placebo‐controlled	 clinical	
trial comprising of 175 infertile men with idiopathic oligoastheno‐
zoospermia.	 We	 found	 a	 significant	 increase	 in	 seminal	 carnitine	
concentration	after	6	months	of	 therapy,	and	a	significant	positive	
association	between	carnitine	and	progressive	spermatozoa	sperm	
motility.	 Interestingly,	higher	progressive	motility	was	found	in	the	
group of patients with higher basal carnitine concentration (before 
therapy). These results align with the report of lower seminal car‐
nitine	 levels	 in	 infertile	men	 than	 in	 fertile	 controls	 (Gurbuz,	Yalti,	
FiCicoglu,	&	Zehir,	2003;	Matalliotakis	et	al.,	2000).	Our	data	further	
demonstrated	 that	 an	 increase	 of	 7.7%	 in	 seminal	 carnitine	 levels	
from basal value is a good predictor of sperm motility recovery. This 
cut‐off value was also significantly associated with the increase in 
progressive sperm motility. These findings also align with that found 
in	other	 studies	 (DeRosa	et	 al.,	2005;	Lenzi	et	 al.,	2003).	 In	a	pla‐
cebo‐controlled,	double‐blind	randomised	study	where	infertile	men	
were	treated	with	2	g/day	LC	and	1	g/day	ALC	for	6	months,	Lenzi	
et al. (2004) observed significant improvements in sperm motility. 
Similarly,	a	study	 including	30	normozoospermic	and	30	 idiopathic	
asthenozoospermia	 men	 treated	 with	 2	g/day	 LC	 for	 3	months	
showed sperm motility recovery in the group with normal values for 
phospholipid	hydroperoxide	glutathione	peroxidase,	a	marker	of	mi‐
tochondrial	structure	and	function	(Garolla	et	al.,	2005).
A	study	with	60	idiopathic	oligoasthenozoospermia	men	treated	
for	6	months	with	either	3	g	LC	and	3	g	ALC,	or	2	g	LC	and	1	g	ALC,	
or	placebo	(Balercia	et	al.,	2005),	showed	clear	beneficial	effects	on	
sperm	kinetics;	however,	a	difference	was	not	found	relative	to	pro‐
gressive	sperm	motility.	Lombardo	et	al.	 (2010)	reported	improved	
Sperm parameter
Cut‐off for 
motility Se Sp PPV NPV
Carnitine increase between T0/
T6	(%)a 
7.7% 53.3 90.0 97.2 22.5
a‐Glucosidase increase between 
T0/T6	(%)a 
3.0% 72.7 81.8 96.0 33.3
Volume increase between T0/T6 
(%)a 
5.9% 55.0 100 100 20.0
Sperm	vitality	increase	between	
T0/T6	(%)b 
5.9 61.4 100 100 37.1
Notes.	Se:	sensitivity;	Sp:	specificity;	PPV:	positive	predictive	value;	NPV:	negative	predictive	value.
aDetection	of	individuals	with	sperm	motility	greater	than	10%.	bDetection of individuals with sperm 
motility	greater	than	20%.	
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changes in the parameter values tested to 
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total sperm motility and forward motility after 3 months of therapy 
with	Proxeed	NF	(LC	250	mg/day	and	ALC	75	mg/day)	in	a	group	of	
32	infertile	men	(sperm	concentration,	10–60	mill/ml;	total	motility,	
5%–40%;	forward	motility,	<15%).	Two	studies	(Ahmed,	Ahsan,	Iqbal,	
&	Burney,	2017;	Matalliotakis	et	al.,	2000)	found	a	significant	posi‐
tive correlation between seminal carnitine levels and sperm motility.
In	contrast,	Sigman	et	al.	(2006),	in	a	double‐blind,	placebo‐con‐
trolled study involving a small number of patients treated with 2 g 
LC	and	1	g	ALC	daily	for	24	months,	reported	no	significant	improve‐
ment	in	sperm	motility.	Recently,	Busetto	et	al.	(2018)	analysed	104	
oligo‐	and/or	astheno‐	and/or	teratozoospermic	men,	with	and	with‐
out	varicocele,	who	received	Proxeed	Plus	or	placebo	for	6	months	
based	on	 a	 randomisation	 schedule.	A	 significant	 increase	 in	 total	
sperm count and progressive sperm motility was demonstrated in 
the	supplemented	group,	with	and	without	varicocele;	no	difference	
was observed in progressive sperm motility after 6 months of treat‐
ment between men with and without varicocele. They concluded 
that	 oxidative	 stress	 has	 a	 negative	 effect	 on	 semen	 parameters,	
and using carnitine and other substances can serve as an efficacious 
therapy to improve male fertility.
α‐Glucosidase,	which	is	normally	present	in	semen	together	with	
LC	and	glycerophosphocholine,	is	a	sensitive	marker	of	epididymal	
function	(Cooper,	Yeung,	Nashan,	Jockenhövel,	&	Nieschlag,	1990).	
We found a significant increase in α‐glucosidase concentration after 
6	months	of	therapy,	which	aligns	with	the	higher	levels	of	α‐gluco‐
sidase	observed	in	fertile	compared	to	infertile	men	by	Zopfgen	et	
al.	(2000),	and	the	positive	correlation	between	α‐glucosidase activ‐
ity	and	motility	by	Roaiah	et	al.	(2007).	Some	studies	did	not	observe	
a difference in α‐glucosidase	activity	 relative	 to	 spermatozoa	mo‐
tility	(Krause	&	Bohring,	1999;	Lenzi	et	al.,	2003;	Said	et	al.,	2009).
Standard	methods	for	ejaculate	analyses	are	often	insufficient	to	
predict	successful	pregnancy;	yet,	increased	sperm	DNA	fragmenta‐
tion has been demonstrated as a good and reliable predictor of male 
infertility	as	well	as	fertilisation	and	pregnancy	(Bungum	et	al.,	2007;	
Simon	et	al.,	2013;	Zhao	et	al.,	2014).	Studies	in	the	last	decade	have	
indicated	a	high	per	cent	of	DNA	fragmentation	in	the	general	popu‐
lation	and	during	IVF	procedures	(Alshahhrani	et	al.,	2014;	Cho	et	al.,	
2017;	Henkel	et	al.,	2004;	Zhao	et	al.,	2014).	In	our	study,	we	noticed	
a	significant	decrease	in	DFI	after	3	months	of	therapy,	followed	by	a	
further significant decrease after an additional 3 months of therapy 
(T6).	We	also	found	that	if	DFI	decreased	by	1%,	the	probability	of	a	
sperm	motility	higher	than	10%	increased	1.105‐fold.
We employed ROC analyses to determine the optimal seminal 
parameters	and	sperm	motility	10%	or	20%.	Results	showed	that	a	
3%	decrease	in	DFI	after	6	months	of	therapy	predicted	a	progres‐
sive	motility	10%	with	a	probability	of	96%.	In	addition,	we	demon‐
strated that the only independent predictor of a progressive motility 
10%	and	20%	for	spermatozoa	 is	a	decrease	 in	DFI.	However,	 the	
capacity	of	DFI	values	in	the	diagnosis	of	motility	20%	is	not	relevant	
from	a	clinical	viewpoint.	Our	data	merely	imply	that	a	change	in	DFI	
is moderately associated with the increase in progressive motility 
after	6	months	of	Proxeed	Plus	therapy.
Scarce	data	exist	regarding	the	effects	of	anti‐oxidative	ther‐
apy	 in	 infertile	men,	and	DFI	values.	Varicocelectomy	 in	 infertile	
men	led	to	a	significant	decrease	in	DFI	values	(Smit	et	al.,	2013).	
Analysis	of	38	couples	undergoing	IVF	revealed	that	the	male	part‐
ners	had	 increased	DFI%,	but	 after	 two	months	of	 therapy	with	
vitamin	 C	 and	 vitamin	 E,	 a	 DFI%	 decrease	 in	 76%	 of	males	 and	
an increased number of successful pregnancies were observed 
(Greco	et	al.,	2005).	In	a	recent	Cochrane	analysis,	a	positive	effect	
owing	 to	 oral	 anti‐oxidative	 therapy	 and	 successful	 pregnancies	
were	suggested;	in	this	analysis,	only	two	papers	had	investigated	
DNA	fragmentation	and	the	authors	reported	a	13%	decrease	 in	
DFI	 in	 patients	 who	 received	 anti‐oxidative	 therapy	 (Showell	 et	
al.,	2014).
In	 this	 study,	we	showed	a	high	probability	of	males	achieving	
progressive	motility	10%	after	6	months	of	therapy;	the	cut‐off	value	
of	5.9%	representing	the	increase	in	sperm	vitality	after	6	months	of	
therapy	is	associated	with	a	progressive	motility	10%	or	20%.	This	
occurrence	 is	 associated	 with	 a	 100%	 probability,	 indicating	 that	
sperm	vitality	is	a	good	predictor	of	progressive	motility.	Aside	from	
this,	we	emphasise	that	simultaneously	determining	DFI	and	vitality	
has the highest diagnostic validity when used to identify patients 
with	10%	progressive	motility	of	spermatozoa.	According	to	WHO	
(2010),	determining	sperm	vitality	is	one	of	the	main	parameters	in	
standard	 semen	 analysis,	 and	 is	 particularly	 important	 in	 samples	
containing	a	high	number	of	immotile	spermatozoa.
In	this	study,	after	6	months	of	therapy	with	the	formulation	of	
LC	and	ALC,	we	observed	significant	beneficial	effects	in	progressive	
motility,	vitality	and	DNA	fragmentation.	These	results	suggest	that	
seminal	levels	of	LC	play	an	essential	role	in	maintaining	male	fertil‐
ity.	Moreover,	these	results	support	the	significance	of	formulations	
that combine metabolic and nutritive factors as a therapy to treat 
male	infertility	and	recover	the	functional	capacity	of	spermatozoa.
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